FY2025 EPS Estimates for ARWR Increased by Cantor Fitzgerald

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) – Stock analysts at Cantor Fitzgerald upped their FY2025 EPS estimates for Arrowhead Pharmaceuticals in a research report issued to clients and investors on Wednesday, November 19th. Cantor Fitzgerald analyst P. Agrawal now anticipates that the biotechnology company will earn ($0.05) per share for the year, up from their previous forecast of ($0.94). The consensus estimate for Arrowhead Pharmaceuticals’ current full-year earnings is ($2.42) per share. Cantor Fitzgerald also issued estimates for Arrowhead Pharmaceuticals’ FY2026 earnings at ($3.58) EPS.

Several other analysts have also recently commented on the company. Royal Bank Of Canada raised their price target on Arrowhead Pharmaceuticals from $45.00 to $52.00 and gave the company an “outperform” rating in a report on Wednesday. HC Wainwright reiterated a “buy” rating and issued a $80.00 price objective on shares of Arrowhead Pharmaceuticals in a research report on Wednesday, October 8th. TD Cowen raised Arrowhead Pharmaceuticals to a “strong-buy” rating in a report on Monday, July 28th. B. Riley upgraded shares of Arrowhead Pharmaceuticals to a “strong-buy” rating in a research report on Monday, August 11th. Finally, The Goldman Sachs Group increased their price target on shares of Arrowhead Pharmaceuticals from $27.00 to $48.00 and gave the company a “neutral” rating in a report on Thursday. Two research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Arrowhead Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus target price of $48.22.

Arrowhead Pharmaceuticals Price Performance

Shares of ARWR opened at $40.45 on Friday. The company has a current ratio of 4.87, a quick ratio of 4.87 and a debt-to-equity ratio of 0.39. The stock’s 50 day moving average is $36.95 and its two-hundred day moving average is $24.56. Arrowhead Pharmaceuticals has a twelve month low of $9.57 and a twelve month high of $43.69. The firm has a market capitalization of $5.59 billion, a PE ratio of -31.60 and a beta of 1.27.

Insiders Place Their Bets

In other news, insider James C. Hamilton sold 20,000 shares of Arrowhead Pharmaceuticals stock in a transaction on Wednesday, October 1st. The stock was sold at an average price of $35.00, for a total transaction of $700,000.00. Following the completion of the transaction, the insider owned 212,122 shares of the company’s stock, valued at $7,424,270. The trade was a 8.62% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Insiders sold a total of 50,000 shares of company stock valued at $1,525,000 over the last quarter. 4.30% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Arrowhead Pharmaceuticals

A number of large investors have recently bought and sold shares of ARWR. iSAM Funds UK Ltd acquired a new position in shares of Arrowhead Pharmaceuticals in the third quarter worth $29,000. Virtus Advisers LLC acquired a new stake in shares of Arrowhead Pharmaceuticals during the second quarter valued at $34,000. Salomon & Ludwin LLC purchased a new stake in Arrowhead Pharmaceuticals during the 3rd quarter worth about $34,000. Nisa Investment Advisors LLC increased its position in Arrowhead Pharmaceuticals by 75.9% during the 2nd quarter. Nisa Investment Advisors LLC now owns 3,032 shares of the biotechnology company’s stock worth $48,000 after purchasing an additional 1,308 shares in the last quarter. Finally, Federated Hermes Inc. acquired a new position in Arrowhead Pharmaceuticals in the 3rd quarter valued at about $52,000. Institutional investors and hedge funds own 62.61% of the company’s stock.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.